Comparison of Her-2, EGFR and Cyclin D1 in Primary Breast Cancer and Paired Metastatic Lymph Nodes: An Immunohistochemical and Chromogenic In Situ Hybridization Study

The significant advance in the development of molecular-targeting drugs has made an evaluation of Her-2, EGFR, and cyclin D1 an important clinical issue in breast cancer patients. This study compared the Her-2, EGFR, and cyclin D1 status of primary tumors as well as their matching lymph node metastases using immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) in 73 breast cancer patients. Her-2, EGFR, and cyclin D1 protein showed a concordance between the primary lesion and the metastatic regional lymph nodes in 82%, 90%, and 63%, respectively. CISH also revealed 92%, 93%, and 85% concordance in the gene amplification status of Her-2, EGFR, and cyclin D1, showing a reasonable agreement between primary tumors and metastatic regional lymph nodes. Although a statistically significant agreement was found in Her-2 expression, a relatively high discordance rate (18%) raises a little concern. Our findings suggest that the Her-2 status can be reliably assessed on primary tumor but a possible difference can be found in Her-2, EGFR, and cyclin D1 status between the primary and the metastatic sites and this possibility should be concerned in patients considering molecular targeted therapy or patients with progress of disease.

[1]  A. Thompson,et al.  Cyclin D1 and breast cancer. , 2006, Breast.

[2]  A. Italiano,et al.  Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  K. Jirström,et al.  Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. , 2005, Cancer research.

[4]  W. Gerald,et al.  EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations , 2005, Modern Pathology.

[5]  J. Robertson,et al.  Overview of tyrosine kinase inhibitors in clinical breast cancer. , 2005, Endocrine-related cancer.

[6]  A. Papanikolaou,et al.  Cyclin D1 in breast cancer pathogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  N. Sneige,et al.  Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma , 2005, Cancer.

[8]  L. Schwartz,et al.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Lal,et al.  Feasibility of Using Tissue Microarrays for the Assessment of HER-2 Gene Amplification by Fluorescence In Situ Hybridization in Breast Carcinoma , 2004, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[10]  K. Wester,et al.  HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review , 2004, British Journal of Cancer.

[11]  Chunlei Wu,et al.  Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis , 2004, Cancer.

[12]  J. Iglehart,et al.  Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer , 1995, Breast Cancer Research and Treatment.

[13]  D. Merkel,et al.  erbB-2 (HER-2) and Breast Cancer Progression , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[14]  L. Middleton,et al.  Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. , 2003, American journal of clinical pathology.

[15]  T. Hwang,et al.  Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients , 2003, Pathology international.

[16]  D. Larsimont,et al.  Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  S. Tsutsui,et al.  EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  M. Kutty,et al.  Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. , 2002, Oncology reports.

[19]  A. Thor.  Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response? , 2001, Journal of the National Cancer Institute.

[20]  H. Moch,et al.  Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. , 2001, Journal of the National Cancer Institute.

[21]  J. Isola,et al.  Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. , 2001, Cancer research.

[22]  Y. Geng,et al.  Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.

[23]  D. Larsimont,et al.  Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[25]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[26]  M. Bui,et al.  Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. , 2000, Annals of clinical and laboratory science.

[27]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, The oncologist.

[29]  T. Rohan,et al.  Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[30]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[31]  R. Foster,et al.  The biologic and clinical significance of lymphatic metastases in breast cancer. , 1996, Surgical oncology clinics of North America.

[32]  J. Bartek,et al.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. , 1994, Cancer research.

[33]  J. Marks,et al.  Maintenance of p53 alterations throughout breast cancer progression. , 1991, Cancer research.

[34]  J. Marks,et al.  Maintenance of p 53 Alterations throughout Breast Cancer Progression 1 , 1991 .

[35]  M. Kraus,et al.  Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. , 1989, Oncogene.

[36]  I. Fidler,et al.  Biological diversity in metastatic neoplasms: origins and implications. , 1982, Science.

[37]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.